Latest period
$0.00
YoY change
-100.0%
5Y CAGR
-100.0%
Peak year (2022)
$1.42M
Cumulative CapEx
$3.09M
CapEx history chart for Ovid Therapeutics (OVID) from 2014 to 2025
Latest: $0.00
CapEx growth chart for Ovid Therapeutics (OVID) from 2014 to 2025
Latest: -100.0%
CapEx history table for Ovid Therapeutics (OVID) from 2014 to 2025
| 2025 | $0.00 | -100.0% | −$71.00K | ||
| 2024 | $71.00K | -48.3% | −$66.45K | ||
| 2023 | $137.46K | -90.3% | −$1.28M | ||
| 2022 | $1.42M | +671.0% | +$1.23M | ||
| 2021 | $184.01K | -52.9% | −$206.67K | ||
| 2020 | $390.68K | +60.1% | +$146.63K | ||
| 2019 | $244.04K | -30.7% | −$107.97K | ||
| 2018 | $352.02K | +642.9% | +$304.63K | ||
| 2017 | $47.39K | -74.9% | −$141.60K | ||
| 2016 | $188.99K | +235.5% | +$132.66K | ||
| 2015 | $56.33K | +3059.4% | +$54.55K | ||
| 2014 | $1.78K | — | — |
- 2025$0.00-100.0%
- 2024$71.00K-48.3%
- 2023$137.46K-90.3%
- 2022$1.42M+671.0%
- 2021$184.01K-52.9%
- 2020$390.68K+60.1%
- 2019$244.04K-30.7%
- 2018$352.02K+642.9%
- 2017$47.39K-74.9%
- 2016$188.99K+235.5%
- 2015$56.33K+3059.4%
- 2014$1.78K—
CapEx values are taken from Ovid Therapeutics's reported cash flow statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About CapEx at Ovid Therapeutics (OVID)
According to Ovid Therapeutics's latest reported financial statements, the company's current CapEx (TTM) is $0.00. Capital expenditures (CapEx) are cash outlays for property, plant, and equipment and other long-lived productive assets — reported on the cash flow statement under investing activities. CapEx funds future capacity (factories, data centers, software, machinery), so rising spend can signal investment in growth, while heavy CapEx reduces free cash flow available to shareholders. We display CapEx as a positive amount (the absolute cash outflow); compare with revenue to gauge capital intensity and with total assets for the asset-base context.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
The 2025 reading of Ovid Therapeutics (OVID) CapEx is $0.00 – plunged 100.0% year-over-year.
Ovid Therapeutics CapEx has contracted on net over the period, with a -100.0% compound annual growth rate over 2020–2025 (5 years).
Ovid Therapeutics CapEx plunged from $1.42M in 2022 to $0.00 in 2025, a 100.0% drawdown.
Across the available history, CapEx reached its high of $1.42M in 2022 and its low of $0.00 in 2025.
Ovid Therapeutics Capital Expenditures by Year
Ovid Therapeutics Capital Expenditures 2025: $0.00
2025's CapEx for Ovid Therapeutics came in at $0.00, plunged 100.0% below 2024. This figure represents the lowest annual value in the available history.
Ovid Therapeutics Capital Expenditures 2024: $71.00K
Ovid Therapeutics posted CapEx of $71.00K in 2024, plunged 48.3% below 2023.
Ovid Therapeutics Capital Expenditures 2023: $137.46K
In 2023, Ovid Therapeutics reported CapEx of $137.46K, plunged 90.3% below 2022.
Ovid Therapeutics Capital Expenditures 2022: $1.42M
Ovid Therapeutics CapEx in 2022 was $1.42M, surged 671.0% from 2021. This figure represents the highest annual value in the available history.
Ovid Therapeutics Capital Expenditures 2021: $184.01K
Ovid Therapeutics CapEx in 2021 was $184.01K.
See more financial history for Ovid Therapeutics (OVID).
Sector peers by CapEx
Healthcare peers of Ovid Therapeutics (OVID), ranked by their latest CapEx
| $14.05B | |
| $7.84B | |
| $4.83B | |
| $4.11B | |
| $3.62B | |
| $2.81B | |
| $1.86B | |
| $1.21B |
- $14.05B
- $7.84B
- $4.83B
- $4.11B
- $3.62B
- $2.81B
- $1.86B
- $1.21B
Frequently asked questions
Ovid Therapeutics (OVID) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation